Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MGN-4893
- Development stage
- Unknown
- Lead developer
- Viridian Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
MGN-4893 is an investigational microRNA-based therapeutic that acts as an inhibitor of microRNA-451. It was developed for the treatment of polycythemia vera, a rare myeloproliferative disorder characterized by excessive production of blood cells and platelets. MicroRNA-451 plays a crucial role in regulating blood cell development, and its inhibition is thought to modulate disease processes in polycythemia vera. MGN-4893 received FDA orphan drug designation in 2011 for this indication but has not advanced beyond preclinical or early discovery stages as of the latest updates. The drug was originally developed by miRagen Therapeutics (now Viridian Therapeutics), which focuses on innovative RNA-based therapies[1][2][6].
Beyond the preview
Go deeper on MGN-4893.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MGN-4893.